Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ADRB3 | P13945 | 16/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.60 |
| ▸ | GABRP | O00591 | 1/20 | 0.48 |
| ▸ | GABRD | O14764 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.48 |
| ▸ | GABRE | P78334 | 1/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667469 | 1.00 | ALOX15 (0.69) | ALOX15ADRB3ADRB1GABRPGABRD | |
| SCHEMBL667470 | 1.00 | ALOX15 (0.69) | ALOX15ADRB3ADRB1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6136774 | 0.99 | ALOX15 (0.71) | ALOX15ADRB3ADRB1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6136778 | 0.99 | ALOX15 (0.71) | ALOX15ADRB3ADRB1GABRPGABRD | |
| Hydrochloric Acid SCHEMBL6136770 | 0.99 | ALOX15 (0.71) | ALOX15ADRB3ADRB1GABRPGABRD | |
| SCHEMBL8478597 | 0.91 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2CYP1A2 | |
| SCHEMBL8478592 | 0.91 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2CYP1A2 | |
| SCHEMBL8478595 | 0.91 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2CYP1A2 | |
| SCHEMBL3511603 | 0.89 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2 | |
| SCHEMBL3511600 | 0.89 | ADRB3 (0.58) | ALOX15ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003744-B1 | 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2005-06-01 | — | — | EP | claimed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | claimed |
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | TREADWAY JUDITH L (US) | 2003-01-02 | — | — | US | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| US-6124457-A | Process and intermediates for a β3 -adrenergic receptor agonist | PFIZER INC. (US) | 2000-09-26 | — | — | US | claimed |
| EP-0994105-A2 | 2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists | Pfizer Products Inc. (US) | 2000-04-19 | — | — | EP | claimed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | claimed |
| US-5977124-A | β-adrenergic agonists | PFIZER INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0920864-A1 | Combination therapy including a specific beta-3 agonist and an anorectic agent | Pfizer Products Inc. (US) | 1999-06-09 | — | — | EP | claimed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0828712-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-03-18 | — | — | EP | claimed |
| EP-0824519-A1 | BETA-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1998-02-25 | — | — | EP | claimed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| WO-1996035670-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | claimed |
| JP-11092372-A | — | — | None | — | — | JP | disclosed |
| WO-1996035671-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996035670-A1 | β-ADRENERGIC AGONISTS | PFIZER INC. (US) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004162-A1 | Use of glycogen phosphorylase inhibitors | PYGL, PYGM, GYS2 | ALOX15 1638/4885ADRB3 2257/4885ADRB1 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.